10.02.07
Isis Pharmaceuticals, Inc. earned $5 million from Ortho-McNeil, Inc. (OMI), a Johnson & Johnson company, for achieving the first development milestone of initializing the Phase I trial of ISIS 325568.
The collaboration, announced in September 2007, includes the licensing of two second-generation antisense drugs, ISIS 325568 and ISIS 377131, for the treatment of metabolic disease. ISIS 325568 was designed to selectively inhibit the production of glucagon receptor and has demonstrated improved glucose control in animal models of Type 2 diabetes.
"We are pleased to have achieved this milestone so early in our collaboration with Ortho-McNeil, Inc.," said Jeffrey Jonas, M.D., executive vice president, Isis Pharmaceuticals. "OMI will be providing all funding for this study, while Isis will be managing the study through to completion before handing all additional development responsibilities over to our partner."
The collaboration, announced in September 2007, includes the licensing of two second-generation antisense drugs, ISIS 325568 and ISIS 377131, for the treatment of metabolic disease. ISIS 325568 was designed to selectively inhibit the production of glucagon receptor and has demonstrated improved glucose control in animal models of Type 2 diabetes.
"We are pleased to have achieved this milestone so early in our collaboration with Ortho-McNeil, Inc.," said Jeffrey Jonas, M.D., executive vice president, Isis Pharmaceuticals. "OMI will be providing all funding for this study, while Isis will be managing the study through to completion before handing all additional development responsibilities over to our partner."